Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-17

FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved a supplemental application for Ozempic to include the oral semaglutide formulation, expanding treatment options to patients with type 2 diabete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OZEMPIC (semaglutide)

Snippet

SUPPL AP for OZEMPIC (ORAL SEMAGLUTIDE)